Salvage chemotherapy in relapsed germ cell tumors

被引:12
作者
Beyer, J
Rick, O
Siegert, W
Bokemeyer, C
机构
[1] Univ Marburg, Dept Hematol & Oncol, D-35033 Marburg, Germany
[2] Dept Hematol & Oncol, Charite, D-13353 Berlin, Germany
[3] Univ Tubingen, Dept Hematol & Oncol, D-72076 Tubingen, Germany
关键词
germ-cell-tumor; prognosis; recurrence; salvage therapy;
D O I
10.1007/PL00007095
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Issues concerning the optimal salvage treatment in patients with germ cell tumors are for the most part controversial. As the majority of patients will suffer systemic relapses, chemotherapy will remain the mainstay of any salvage treatment. However. the question of whether to use conventional-dose or high-dose chemotherapy (HDCT) immediately arises. Prognostic factors have recently been recognized as an aid in this decision. However, as reliable data are lacking for many clinical scenarios, the salvage treatment of germ-cell tumors continues to be a therapeutic challenge.
引用
收藏
页码:90 / 93
页数:4
相关论文
共 21 条
  • [1] LATE RELAPSE OF TESTICULAR CANCER
    BANIEL, J
    FOSTER, RS
    GONIN, R
    MESSEMER, JE
    DONOHUE, JP
    EINHORN, LH
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (05) : 1170 - 1176
  • [2] High-dose chemotherapy as salvage treatment in germ cell tumors: A Multivariate analysis of prognostic variables
    Beyer, J
    Kramar, A
    Mandanas, R
    Linkesch, W
    Greinix, A
    Droz, JP
    Pico, JL
    Diehl, A
    Bokemeyer, C
    Schmoll, HJ
    Nichols, CR
    Einhorn, LH
    Siegert, W
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (10) : 2638 - 2645
  • [3] BEYER J, 1994, WORLD J UROL, V12, P207
  • [4] BEYER J, 1999, P AM SOC CLIN ONCOL, V18, P1255
  • [5] Bokemeyer C, 1996, ANN ONCOL, V7, P31
  • [6] First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis
    Bokemeyer, C
    Kollmannsberger, C
    Meisner, C
    Harstrick, A
    Beyer, J
    Metzner, B
    Hartmann, JT
    Schmoll, HL
    Einhorn, L
    Kanz, L
    Nichols, C
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) : 3450 - 3456
  • [7] BOSI G, 1997, NEW ENGL J MED, V337, P242
  • [8] Prognostic factors in patients progressing after cisplatin based chemotherapy for malignant non-seminomatous germ cell tumours
    Fosså, SD
    Stenning, SP
    Gerl, A
    Horwich, A
    Clark, PI
    Wilkinson, PM
    Jones, WG
    Williams, MV
    Oliver, RT
    Newlands, ES
    Mead, GM
    Cullen, MH
    Kaye, SB
    Rustin, GJS
    Cook, PA
    [J]. BRITISH JOURNAL OF CANCER, 1999, 80 (09) : 1392 - 1399
  • [9] Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor
    Loehrer, PJ
    Gonin, R
    Nichols, CR
    Weathers, T
    Einhorn, LH
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (07) : 2500 - 2504
  • [10] SALVAGE THERAPY IN RECURRENT GERM-CELL CANCER - IFOSFAMIDE AND CISPLATIN PLUS EITHER VINBLASTINE OR ETOPOSIDE
    LOEHRER, PJ
    LAUER, R
    ROTH, BJ
    WILLIAMS, SD
    KALASINSKI, LA
    EINHORN, LH
    [J]. ANNALS OF INTERNAL MEDICINE, 1988, 109 (07) : 540 - 546